Twist Bioscience Corporation Repayments of Long-Term Debt
Twist Bioscience Corporation (TWST) reported Repayments of Long-Term Debt of $0 for the 12-month period ending 2024-09-30, per its 10-K filed 2024-11-18.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2024-11-18
- Twist Bioscience Corporation repayments of long-term debt for the quarter ending 2023-09-30 was $0.00.
- Twist Bioscience Corporation repayments of long-term debt for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Twist Bioscience Corporation repayments of long-term debt for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Twist Bioscience Corporation repayments of long-term debt for the quarter ending 2021-09-30 was $833.00K, a 0.00% change year-over-year.
- Twist Bioscience Corporation repayments of long-term debt for fiscal 2024 was $0.00.
- Twist Bioscience Corporation repayments of long-term debt for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Twist Bioscience Corporation repayments of long-term debt for fiscal 2022 was $1.56M, a 53.26% decline from fiscal 2021.
- Twist Bioscience Corporation repayments of long-term debt for fiscal 2021 was $3.33M, a 0.00% change from fiscal 2020.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-K · filed 2024-11-18 | |||
| 2023-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | $0.00 10-K · filed 2024-11-18 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-07 | |||
| 2022-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2024-11-18 | $1.56M 10-K · filed 2024-11-18 | |
| 2022-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | $1.56M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $1.56M 10-Q · filed 2022-05-06 | |||
| 2021-09-30 | $833.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | $1.67M derived: sum of 2 quarters · filed 2023-11-21 | $2.50M derived: sum of 3 quarters · filed 2023-11-21 | $3.33M 10-K · filed 2023-11-21 |
| 2021-06-30 | $833.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-08 | $1.67M derived: sum of 2 quarters · filed 2022-08-08 | $2.50M 10-Q · filed 2022-08-08 | $3.33M derived: sum of 4 quarters · filed 2023-06-05 |
| 2021-03-31 | $834.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-06 | $1.67M 10-Q · filed 2022-05-06 | $2.50M derived: sum of 3 quarters · filed 2023-06-05 | $3.33M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-12-31 | $833.00K 10-Q · filed 2021-02-09 | $1.67M derived: sum of 2 quarters · filed 2023-06-05 | $2.50M derived: sum of 3 quarters · filed 2023-06-05 | $3.33M derived: sum of 4 quarters · filed 2023-06-05 |
| 2020-09-30 | $833.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-05 | $1.67M derived: sum of 2 quarters · filed 2023-06-05 | $2.50M derived: sum of 3 quarters · filed 2023-06-05 | $3.33M 10-K/A · filed 2023-06-05 |
| 2020-06-30 | $833.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-09 | $1.67M derived: sum of 2 quarters · filed 2021-08-09 | $2.50M 10-Q · filed 2021-08-09 | $3.33M derived: sum of 4 quarters · filed 2021-11-23 |
| 2020-03-31 | $834.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-07 | $1.67M 10-Q · filed 2021-05-07 | $2.50M derived: sum of 3 quarters · filed 2021-11-23 | $3.33M derived: sum of 4 quarters · filed 2021-11-23 |
| 2019-12-31 | $833.00K 10-Q · filed 2021-02-09 | $1.67M derived: sum of 2 quarters · filed 2021-11-23 | $2.50M derived: sum of 3 quarters · filed 2021-11-23 | |
| 2019-09-30 | $833.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-23 | $1.67M derived: sum of 2 quarters · filed 2021-11-23 | $2.50M 10-K · filed 2021-11-23 | |
| 2019-06-30 | $834.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-12 | $1.67M 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $833.00K 10-Q · filed 2020-05-13 | |||
| 2017-09-30 | $4.17M 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |